



Official reprint from UpToDate®

www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Wolters Kluwer

Gastric intestinal metaplasia

AUTHOR: Douglas Morgan, MD, MPH**SECTION EDITOR:** Mark Feldman, MD, MACP, AGAF, FACP**DEPUTY EDITOR:** Shilpa Grover, MD, MPH, AGAF

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: **Sep 2023**.

This topic last updated: **Mar 30, 2022**.

INTRODUCTION

Globally, gastric cancer is the third leading cause of cancer mortality and the leading cause of infection-associated cancers. Gastric intestinal metaplasia (GIM) is an intermediate precancerous gastric lesion in the gastric cancer cascade of chronic gastritis, atrophic gastritis, intestinal metaplasia (IM), dysplasia, and adenocarcinoma [1]. Although the risk of gastric cancer is increased in patients with GIM, the absolute risk is modest. Specific subsets of patients with GIM may be at higher risk for progression.

This topic will review the epidemiology, natural history, diagnosis, and management of distal (noncardia) GIM. Screening for gastric cancer and the management of IM at the gastric cardia (located immediately distal to the squamocolumnar junction and proximal to the oxyntic mucosa) and its distinction from Barrett's esophagus are discussed in detail separately. (See "[Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis](#)", section on '[Intestinal metaplasia at GEJ](#)' and "[Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging](#)" and "[Early gastric cancer: Treatment, natural history, and prognosis](#)" and "[Gastric cancer screening](#)".)

TERMINOLOGY

GIM is defined as the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium [2].

Classification — Several GIM classification systems are in use [3-6].

- GIM topographic extent – Based on the extent of gastric involvement on histology, GIM is classified as extensive versus limited [3,4,7,8]:
 - Extensive IM – GIM involving the corpus and either the antrum and/or incisura angularis. GIM of the corpus alone is also considered a surrogate for extensive metaplasia, as antral metaplasia is usually also present, but may have been missed on biopsy given the patchy distribution.
 - Limited IM – GIM involving the antrum or incisura.
- GIM histologic subtypes
 - Based on the histology with hematoxylin and eosin staining (H&E stain):
 - Complete IM is defined by the presence of small intestinal-type mucosa with goblet cells that secrete sialomucins, a brush border, and eosinophilic enterocytes ([picture 1](#)).
 - Incomplete IM is defined by the presence of colonic-type epithelium with multiple, irregular mucin droplets of variable size in the cytoplasm and absence of a brush border ([picture 2](#)).
 - Based on mucin expression – IM has also been subtyped based on mucin expression, but its use is mainly limited to research settings. In IM, the original gastric mucins, which have a neutral pH, are replaced by acid mucins, which may be sialic or sulfated. Using a combination Alcian blue and high-iron diamine stain, GIM is classified based on the types of mucins expressed and morphology into the following types [5]:
 - Type I (complete) IM expresses only sialomucins
 - Type II (incomplete) IM expresses a mixture of gastric (neutral) mucins and intestinal sialomucins
 - Type III (incomplete) IM expresses sulfomucins
 - Combined periodic acid Schiff-AB staining may also be used to discriminate between normal epithelium and IM [9]. It is unclear whether this approach adds to risk stratification beyond the improved identification of incomplete IM [7]. Immunohistochemical stains may also be used for GIM confirmation (eg, MUC2).
- Updated Sydney system – The operative link for gastritis assessment (OLGA) and operative link on GIM (OLGIM) staging systems are used to evaluate the severity and extent of

atrophy and IM. The severity of gastric atrophy and IM are graded in the antrum/incisura and corpus. OLGA and OLGIM are primarily used in the research setting. Stages III and IV represent more severe extensive disease and correlate with a higher risk of progression ([table 1](#) and [table 2](#)) [4,10,11]. (See "[Metaplastic \(chronic\) atrophic gastritis](#)", section on 'Diagnosis'.)

EPIDEMIOLOGY AND PATHOGENESIS

Estimates of the global prevalence of GIM vary widely due to the variations in gastric cancer incidence [12-15]. GIM prevalence in high-incidence regions ranges between 19 to 24 percent [12]. In low gastric cancer incidence regions such as the United States and in northern Europe, GIM prevalence is approximately 5 percent [12]. Prevalence of GIM increases with age and is higher in areas with high prevalence of *Helicobacter pylori* (*H. pylori*), in men, and in current smokers [13,16-18]. (See "[Epidemiology of gastric cancer](#)" and "[Gastric cancer: Pathology and molecular pathogenesis](#)", section on 'Intestinal metaplasia'.)

GIM is a premalignant stage in the gastric cancer cascade through a series of well-defined and recognizable precursors [19]. The gastric adenocarcinoma multistage model, the "Correa cascade," suggests that a combination of host genetic factors and responses, *H. pylori* genomics, with modulation by dietary and environmental factors, predispose to early pan-gastric mucosal inflammation, which in turn results in gastric atrophy, IM, dysplasia, and adenocarcinoma [20-22]. This model is most applicable to the intestinal subtype of gastric cancer. While there may be reversal of gastric atrophy with *H. pylori* eradication, GIM is considered as a "point of no return" in the multistage model, although this remains an ongoing debate.

The metaplastic foci often first appear at the antrum-corpus junction, and frequently at the incisura angularis. As the process advances, the foci enlarge and coalesce, extending to the neighboring mucosa in both the antrum and the corpus [7]. As atrophic and metaplastic glands replace original glands, normal gastric secretions decrease, leading to hypochlorhydria and to low levels of pepsinogen produced by the chief cells of the corpus, and to high circulating levels of gastrin produced by antral G cells. The first metaplastic glands seen in the gastric mucosa phenotypically resemble those of the small intestine, with eosinophilic absorptive enterocytes with a brush border, alternating with mucus-producing goblet cells (complete or small IM). More advanced stages are characterized by phenotypic changes that are similar to colonic mucosa with the glands being lined by irregular goblet cells (incomplete or colonic metaplasia) ([picture 1](#) and [picture 2](#)). In a subset of patients, foci of dysplasia may develop within areas

of IM. (See "[Gastric cancer: Pathology and molecular pathogenesis](#)", section on 'Intestinal versus diffuse types'.)

CLINICAL FEATURES

GIM in general does not cause specific symptoms and is often found incidentally in patients undergoing upper endoscopy for dyspepsia. However, intestinal metaplasia is associated with gastric hypochlorhydria, which may result in small intestinal bacterial overgrowth with symptoms of bloating, abdominal discomfort, and diarrhea. (See "[Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis](#)", section on 'Clinical features'.)

CANCER RISK

Incidence — Patients with GIM are thought to be at increased risk for gastric cancer but the absolute risk appears to be low in areas of low gastric cancer incidence, such as North America and northern Europe. A limited number of studies have evaluated the rate of progression to gastric cancer in patients with GIM, and estimates from small studies have varied widely and depend upon the background incidence of gastric cancer [23-26]. In European, Asian, and United States populations, the rates of gastric cancer vary between 1.1 and 2.0 per 1000 person-years, and up to 3.0 per 1000 person-years if high-grade dysplasia is included [11,25,27-33].

Risk factors — Risk for gastric cancer may be higher among individuals with incomplete versus complete GIM on histology, extensive versus limited GIM, and those with a family history of gastric cancer in a first-degree relative [11,26,28,34-37]. In a meta-analysis of seven studies, having incomplete versus complete GIM was associated with a threefold increased risk of incident gastric cancer (over 3 to 13 years follow-up; relative risk [RR] 3.3, 95% confidence interval [CI], 1.9-5.6) [38]. Among patients with GIM who had biopsies obtained from both the gastric antrum/incisura and body, extensive GIM versus limited involvement (ie, including involvement of at least the gastric body versus GIM of the antrum and/or incisura, respectively) was associated with a twofold higher pooled RR of incident gastric cancer (RR 2.07, 95% CI, 0.97-4.42). Among patients with GIM, having a family history of a first-degree relative with gastric cancer was associated with 4.5-fold increased risk for incident gastric cancer based on three studies (RR 4.5, 95% CI, 1.3-15.5).

Race and ethnicity may also play a role in GIM progression [17,18,31,32,39]. Immigrant populations from high-risk regions to low-incidence regions have a persistent increased risk of gastric cancer [39]. However, data on the influence of other gastric cancer risk factors (eg,

smoking and alcohol use, pernicious anemia or autoimmune gastritis, *Helicobacter pylori* infection) on rates of GIM progression are lacking [12,38]. (See ['Management'](#) below.)

DIAGNOSIS

The diagnosis of GIM may be suspected based on endoscopic findings, but is established by histology. (See ['Gastric topographic biopsy mapping'](#) below and ["Gastric cancer: Pathology and molecular pathogenesis"](#), section on ['Intestinal metaplasia'](#).)

Upper endoscopy with biopsy — Endoscopically, GIM has the appearance of small grey-white, slightly elevated plaques surrounded by mixed patchy pink and pale areas of mucosa causing an irregular, uneven surface. GIM may also have the appearance of mottled patchy erythema. High-quality endoscopy examination is needed to detect GIM. We perform upper endoscopy with high-resolution scopes and use enhanced imaging with narrow band imaging (NBI) when GIM is suspected. NBI is a high-resolution endoscopic technique that enhances the fine structure of the mucosal surface without the use of dyes. NBI should be combined with magnification endoscopy to improve visualization of surface and vascular patterns for GIM detection. The light blue crest pattern and/or marginal turbid band are suggestive of GIM [40].

Other endoscopic measures that may increase the yield of upper endoscopy include adequate examination time (seven minutes intubation to extubation), mucosal cleaning, and air insufflation for mucosal visualization [41-43]. Visual inspection of the stomach should be accompanied by photographic documentation (antrum, pylorus, incisura, lesser curve, greater curve, fundus, and cardia) and gastric biopsy mapping [44,45]. Other station-based screening protocols (with 22 or 26 pictures) have also been proposed whereby each area of the stomach is viewed and photographed [44,46].

Several studies have demonstrated that white light endoscopy alone (without high-resolution or enhanced imaging) has low sensitivity for GIM and cannot accurately distinguish between nonatrophic gastritis, multifocal atrophic gastritis, and IM [47-49]. In addition, interobserver variability often limits the utility of endoscopic findings [50]. As compared with histology, NBI with magnification endoscopy has a sensitivity and specificity of 89 and 93 percent, respectively [40,51-55]. Further studies are needed to validate NBI patterns in GIM [56-60]. (See ["Magnification endoscopy"](#) and ["Barrett's esophagus: Evaluation with optical chromoscopy"](#), section on ['Principles'](#).)

Gastric topographic biopsy mapping — Diagnostic findings of GIM on gastric biopsy include replacement of the surface, foveolar, and glandular epithelium in the oxyntic and/or antral

mucosa by metaplastic epithelium. However, gastric topographic mapping is required to determine the type and extent of metaplasia and guide management ([algorithm 1](#)) [7,9,24]. For gastric topographic mapping, biopsies are obtained from a minimum of five nontargeted biopsy sites (the lesser and greater curvatures of both the antrum and corpus, and the incisura angularis), with one or two biopsies ("bites") per site ([figure 1](#)) [3]. Specimens should be placed in a minimum of two bottles, for the corpus and antrum with incisura, respectively [61-67]. In addition, targeted biopsies should be obtained from irregular areas of the mucosa to rule out dysplasia and early gastric cancer. Pathology reports should include comments on the GIM subtypes, which are routine with H&E staining. (See '[Terminology](#)' above.)

Tests with unclear role

- **Other endoscopic modalities** – Several other endoscopic modalities have been evaluated to detect early gastric cancer and other gastric precancerous lesions, and endoscopy imaging technologies are in rapid evolution [68,69]. However, further studies are needed before they can be routinely recommended [70-72].
 - Magnification chromoendoscopy – The use of magnification chromoendoscopy for GIM and early gastric cancer is limited to specialized centers, primarily in Asia. Magnification chromoendoscopy involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis with magnification endoscopy. Although several agents (eg, [methylene blue](#), acetic acid) have been studied, [indigo carmine](#) is the most commonly used stain [73,74]. Magnification chromoendoscopy requires specialized training and lengthens the procedure duration. While some studies have demonstrated a significant improvement in detection of GIM with the use of chromoendoscopy with indigo carmine, discordant data have also been published. (See "[Chromoendoscopy](#)" and "[Magnification endoscopy](#)", section on '[Stomach](#)').)
 - Confocal endomicroscopy – Confocal endomicroscopy is based upon the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. The laser is focused at a specific depth and only light reflected back from that plane is refocused and able to pass through the pinhole confocal aperture. As a result, scattered light from above and below the plane of interest is not detected, increasing spatial resolution. The area being examined is scanned in the horizontal and vertical planes and an image is reconstructed. The applications and efficacy of confocal microscopy are discussed in detail separately. (See "[Confocal laser endomicroscopy and endocytoscopy](#)".)

- **Biomarkers** – Serum pepsinogen I and the pepsinogen I/II ratio have been studied extensively as a screening modality for gastric atrophy, GIM, dysplasia, and adenocarcinoma in Asian and European populations [75-77]. The testing has been combined with the *Helicobacter pylori* serology and/or Gastrin 17 in some protocols [78-80]. The limited sensitivity and specificity of pepsinogen and related assays testing preclude its use. (See "[Gastric cancer screening](#)", section on '[Serum pepsinogen](#)'.)

POST-DIAGNOSTIC EVALUATION

Assessment of cancer risk — Patients with GIM are considered at high-risk for gastric cancer if they have any one of the following [39,41,81-83]:

- Family history of gastric cancer in a first-degree relative
- Incomplete GIM
- Extensive or corpus GIM
- Racial/ethnic minorities and/or immigrants from high-incidence areas

Determining the type and extent of GIM requires gastric topographic mapping ([algorithm 1](#)) [7,9,24]. If GIM is suspected on the index upper endoscopy, biopsy mapping may be performed. However, if GIM is discovered incidentally on a gastric biopsy but without complete biopsy mapping, the decision to perform a repeat upper endoscopy and the timing of the procedure is based on risk factors for gastric adenocarcinoma (eg, family history of gastric cancer, racial/ethnic minorities, and/or immigrants from high-incidence areas). (See '[Endoscopic surveillance in selected patients](#)' below and '[Gastric topographic biopsy mapping](#)' above.)

Assessment of family cancer history is important in determining cancer risk and should include a cancer history in first- and second-degree relatives. Familial clustering of gastric cancer occurs in approximately 10 percent of cases. However, hereditary gastric cancer syndromes account for approximately 1 to 3 percent of cases and include three main subgroups: hereditary diffuse gastric cancer, familial intestinal gastric cancer, and other single-gene syndromes associated with an increased risk of gastric adenocarcinoma (eg, Lynch syndrome, Cowden syndrome, Peutz Jegher syndrome, familial adenomatous polyposis).

Individuals with any one of the following should be referred for genetic evaluation for a hereditary gastric cancer syndrome:

- Gastric cancer in one family member before age 40
- Gastric cancer in two first-degree/second-degree relatives with one diagnosis before age 50

- Gastric cancer in three first-degree/second-degree relatives independent of age

Screening for *Helicobacter pylori* (H. pylori) — Infection with *H. pylori* is initially assessed by the histologic evaluation of gastric biopsy samples [84]. However, if the histology does not demonstrate evidence of *H. pylori*, noninvasive testing with serology should be performed. *H. pylori* organism loads may decrease with the onset of precancerous lesions and adenocarcinoma, thereby reducing biopsy sensitivity. In the event of negative biopsies for *H. pylori*, infection status should be determined with serology. Any patient with positive serology who does not have a definitive history of having been treated for *H. pylori* should receive treatment, even if biopsies are negative. (See "[Indications and diagnostic tests for *Helicobacter pylori* infection in adults](#)", section on '[Noninvasive testing](#)' and "[Treatment regimens for *Helicobacter pylori* in adults](#)".)

MANAGEMENT

General measures in all patients — General measures to decrease the risk of gastric cancer include smoking cessation, moderation of alcohol intake, and eradication of *Helicobacter pylori* (*H. pylori*). *H. pylori* is a known risk factor for gastric cancer [24]. Eradication of *H. pylori* appears to reverse the histologic changes in the majority of patients with chronic nonatrophic gastritis and in many patients with multifocal atrophic gastritis, but it is less conclusive for those with GIM [85-88]. Although eradication therapy does not reverse GIM, it may slow the progression to gastric cancer [86,89]. Persistent infection and/or reinfection appears to affect the risk of progression [90]. In patients with GIM who have undergone endoscopic treatment for early gastric cancer or surgical resection for a gastric adenocarcinoma, eradication has been shown to decrease the risk of future adenocarcinoma [91,92]. (See "[Early gastric cancer: Treatment, natural history, and prognosis](#)", section on '[Helicobacter pylori infection](#)'.)

Endoscopic surveillance in selected patients — In individuals with high-risk GIM, we suggest surveillance upper endoscopy which includes a detailed visual inspection, narrow band imaging if there is local expertise, and gastric biopsy mapping ([algorithm 1](#)). High-risk GIM groups include patients with any one of the following [39,41,81-83]:

- Family history of gastric cancer in a first-degree relative
- Incomplete GIM
- Extensive or corpus GIM
- Racial/ethnic minorities in the United States (including African Americans, Hispanics, and Asians)

- First-generation immigrants from high-incidence areas (eg, Eastern Asia, mountainous Latin America)

Evidence suggests that surveillance may lead to early detection of gastric cancer and improved survival [11,93-95]. However, prospective studies are needed to determine the optimal surveillance intervals. Our recommendations for surveillance, depending on the type and extent of IM, are based on expert opinion and are largely consistent with other guidelines [41,81,82]. The role of surveillance and management of gastric cancer risk in patients with hereditary gastric cancer syndromes is discussed in detail separately. (See "[Hereditary diffuse gastric cancer](#)" and "[Li-Fraumeni syndrome](#)" and "[Lynch syndrome \(hereditary nonpolyposis colorectal cancer\): Clinical manifestations and diagnosis](#)" and "[Clinical manifestations and diagnosis of familial adenomatous polyposis](#)" and "[Overview of hereditary breast and ovarian cancer syndromes](#)".)

Extensive or incomplete IM — In patients with extensive IM or incomplete IM, we perform endoscopic surveillance for gastric cancer at the three-year interval [96,97]. Although other guidelines have suggested that those with a family history and extensive or incomplete IM undergo more intense (one to two year) surveillance endoscopy, and evidence to support this recommendation are lacking [81]. (See '[Upper endoscopy with biopsy](#)' above.)

Limited or complete GIM and additional gastric cancer risk factor — In patients with limited or complete GIM and a risk factor for gastric cancer (eg, family history of gastric cancer in a first-degree relative [without a hereditary gastric cancer syndrome], persistent *H. pylori* gastritis, pernicious anemia), we suggest endoscopic surveillance for gastric cancer every three years. In patients with limited or complete GIM who do not have additional risk factors for gastric cancer, evidence to support routine endoscopic surveillance are lacking [41,81,82]. However, GIM surveillance should be driven by shared patient-physician decision making.

Unclear role of chemoprevention — Definitive evidence to support the use of chemoprevention agents in patients with GIM is lacking. Although observational studies have suggested a benefit of [aspirin](#), nonsteroidal anti-inflammatory drugs, and cyclo-oxygenase-2 inhibitors in decreasing the risk of gastric cancer as well as the regression of IM with [celecoxib](#) use, there are no randomized controlled trials [98-102]. In addition, studies that have evaluated the effect of antioxidant vitamin supplementation (eg, ascorbic acid, [beta-carotene](#)) on the risk of progression of gastric precancerous lesions have yielded inconsistent results [103-107].

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "[Society guideline links: Gastric intestinal metaplasia](#)".)

SUMMARY AND RECOMMENDATIONS

- GIM is characterized by the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium. (See '[Terminology](#)' above and '[Classification](#)' above.)
- GIM is an important premalignant stage in the gastric cancer cascade through a series of well-defined and recognizable precursors. The gastric adenocarcinoma multistage model, the "Correa cascade," suggests that a combination of host genetic factors and responses, *Helicobacter pylori* (*H. pylori*) genomics, with modulation by dietary and environmental factors, predispose to early pan-gastric mucosal inflammation, which in turn results in gastric atrophy, IM, dysplasia, and adenocarcinoma. (See '[Epidemiology and pathogenesis](#)' above.)
- Patients with GIM are thought to be at increased risk for gastric cancer but the absolute risk appears to be modest in areas of low gastric cancer incidence (2.5 per 1000 person-years). However, among patients with GIM, the risk of gastric cancer is higher in individuals with extensive and incomplete IM. (See '[Cancer risk](#)' above and '[Classification](#)' above.)
- GIM in general does not cause specific symptoms and is often diagnosed incidentally in patients undergoing upper endoscopy for dyspepsia. However, it is associated with gastric hypochlorhydria, which may result in small intestinal bacterial overgrowth with symptoms of bloating, abdominal discomfort, and diarrhea. On upper endoscopy, GIM has a nonspecific appearance and involved mucosa may have rough or villous appearance, or may be seen as thin, white mucosal deposits. (See '[Clinical features](#)' above.)
- The diagnosis of GIM may be suspected based on endoscopic findings, but is established by histology. High-quality endoscopy examination is needed to improve detection. We perform upper endoscopy with narrow band imaging (NBI) and biopsy mapping ([figure 1](#)). (See '[Diagnosis](#)' above.)
- Patients with GIM are considered at increased risk for gastric cancer if they have any one of the following (see '[Classification](#)' above and '[Assessment of cancer risk](#)' above):

- Family history of gastric cancer in a first-degree relative
- Incomplete GIM
- Extensive or corpus GIM
- Racial/ethnic minorities in the United States (including African Americans, Hispanics, and Asians)
- First-generation immigrants from high-incidence areas (eg, Eastern Asia, mountainous Latin America)

Determining the type and extent of GIM requires gastric topographic mapping ([figure 1](#)).

- General measures to decrease the risk of GIM progression to gastric cancer include smoking cessation, moderation of alcohol intake, and eradication of *H. pylori*. Although eradication of *H. pylori* does not reverse GIM, it may slow progression to gastric cancer. (See '[General measures in all patients](#)' above.)
- In individuals with high-risk GIM, we perform surveillance upper endoscopy at the three-year interval ([algorithm 1](#)). Surveillance endoscopic evaluation includes a detailed visual inspection with high-resolution endoscopes, NBI if there is local expertise, and gastric biopsy mapping. (See '[Management](#)' above.)

ACKNOWLEDGMENT

The UpToDate editorial staff acknowledges Pelayo Correa, MD, who contributed to an earlier version of this topic review.

Use of UpToDate is subject to the [Terms of Use](#).

REFERENCES

1. Correa P. The biological model of gastric carcinogenesis. *IARC Sci Publ* 2004; :301.
2. Antonioli DA. Gastric carcinoma and its precursors. In: *Gastrointestinal Pathology*, Goldman H, Appelman HD, Kaufman N (Eds), United States and Canadian Academy of Pathology Monograph in Pathology No. 31, Williams & Wilkins, Baltimore 1990. p.144.
3. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; 20:1161.

4. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc* 2010; 71:1150.
5. Filipe MI, Muñoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994; 57:324.
6. Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. *Gastroenterology* 2010; 138:2207.
7. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. *Am J Gastroenterol* 2010; 105:493.
8. de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. *Gastrointest Endosc* 2009; 70:18.
9. González CA, Sanz-Anquela JM, Gisbert JP, et al. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. *Int J Cancer* 2013; 133:1023.
10. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. *Dig Liver Dis* 2008; 40:650.
11. den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. *Gut* 2019; 68:585.
12. Altayar O, Davitkov P, Shah SC, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors. *Gastroenterology* 2020; 158:732.
13. Fennerty MB, Emerson JC, Sampliner RE, et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. *Cancer Epidemiol Biomarkers Prev* 1992; 1:293.
14. den Hoed CM, van Eijck BC, Capelle LG, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. *Eur J Cancer* 2011; 47:1211.
15. Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. *Eur J Gastroenterol Hepatol* 1994; 6 Suppl 1:S79.
16. Sonnenberg A, Genta RM. Changes in the Gastric Mucosa With Aging. *Clin Gastroenterol Hepatol* 2015; 13:2276.
17. Huang RJ, Ende AR, Singla A, et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. *Gastrointest Endosc* 2020; 91:70.

18. Tan MC, Mallepally N, Liu Y, et al. Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. *Am J Gastroenterol* 2020; 115:381.
19. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. *Lancet* 1975; 2:58.
20. Polk DB, Peek RM Jr. *Helicobacter pylori*: gastric cancer and beyond. *Nat Rev Cancer* 2010; 10:403.
21. Correa P, Malcom G, Schmidt B, et al. Review article: Antioxidant micronutrients and gastric cancer. *Aliment Pharmacol Ther* 1998; 12 Suppl 1:73.
22. Amieva M, Peek RM Jr. Pathobiology of *Helicobacter pylori*-Induced Gastric Cancer. *Gastroenterology* 2016; 150:64.
23. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. *Cancer Res* 1990; 50:4737.
24. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European *Helicobacter* Study Group (EHSg), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; 44:74.
25. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; 134:945.
26. González CA, Pardo ML, Liso JM, et al. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. *Int J Cancer* 2010; 127:2654.
27. Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. *BMJ* 2015; 351:h3867.
28. González CA, Sanz-Anquela JM, Companioni O, et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. *J Gastroenterol Hepatol* 2016; 31:953.
29. Plummer M, van Doorn LJ, Franceschi S, et al. *Helicobacter pylori* cytotoxin-associated genotype and gastric precancerous lesions. *J Natl Cancer Inst* 2007; 99:1328.
30. Kim N, Park RY, Cho SI, et al. *Helicobacter pylori* infection and development of gastric cancer in Korea: long-term follow-up. *J Clin Gastroenterol* 2008; 42:448.
31. Reddy KM, Chang JI, Shi JM, Wu BU. Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System. *Clin Gastroenterol*

- Hepatology 2016; 14:1420.
32. Li D, Bautista MC, Jiang SF, et al. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study. *Am J Gastroenterol* 2016; 111:1104.
 33. Lee TY, Wang RC, Lee YC, et al. The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study. *J Clin Gastroenterol* 2016; 50:532.
 34. Sossai P, Barbazza R. Intestinal metaplasia and dysplasia in gastric ulcer and its tissue repair. *Am J Gastroenterol* 1990; 85:829.
 35. Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. *Gut* 1990; 31:1097.
 36. Fang DC, Liu WW. Subtypes of intestinal metaplasia and gastric carcinoma. A clinicoendoscopic follow-up of 112 cases. *Chin Med J (Engl)* 1991; 104:467.
 37. Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after *Helicobacter pylori* eradication. *Gastrointest Endosc* 2016; 84:618.
 38. Gawron AJ, Shah SC, Altayar O, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes. *Gastroenterology* 2020; 158:705.
 39. Pabla BS, Shah SC, Corral JE, Morgan DR. Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2020; 18:347.
 40. Uedo N, Ishihara R, Iishi H, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. *Endoscopy* 2006; 38:819.
 41. Gupta S, Li D, El Serag HB, et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. *Gastroenterology* 2020; 158:693.
 42. Emura F, Sharma P, Arantes V, et al. Principles and practice to facilitate complete photodocumentation of the upper gastrointestinal tract: World Endoscopy Organization position statement. *Dig Endosc* 2020; 32:168.
 43. Mier PD, van den Hurk JJ. Lysosomal hydrolases of the epidermis. I. Glycosidases. *Br J Dermatol* 1975; 93:1.
 44. Emura F, Rodriguez-Reyes C, Giraldo-Cadavid L. Early Gastric Cancer: Current Limitations and What Can Be Done to Address Them. *Am J Gastroenterol* 2019; 114:841.
 45. Machaca Quea NR, Emura F, Barreda Bolaños F, et al. Effectiveness of systematic alphanumeric coded endoscopy for diagnosis of gastric intraepithelial neoplasia in a low

- socioeconomic population. *Endosc Int Open* 2016; 4:E1083.
46. Yao K. The endoscopic diagnosis of early gastric cancer. *Ann Gastroenterol* 2013; 26:11.
 47. Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. *Gastrointest Endosc* 1990; 36:544.
 48. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. *Gastroenterology* 1995; 108:917.
 49. Redéen S, Petersson F, Jönsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and *Helicobacter pylori* infection in a general population sample. *Endoscopy* 2003; 35:946.
 50. Laine L, Cohen H, Sloane R, et al. Interobserver agreement and predictive value of endoscopic findings for *H. pylori* and gastritis in normal volunteers. *Gastrointest Endosc* 1995; 42:420.
 51. Gonen C, Simsek I, Sarioglu S, Akpinar H. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of *Helicobacter pylori* gastritis in routine clinical practice: a prospective study. *Helicobacter* 2009; 14:12.
 52. Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, *Helicobacter pylori*-associated gastritis, and gastric atrophy. *Endoscopy* 2007; 39:202.
 53. Tahara T, Shibata T, Nakamura M, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. *Gastrointest Endosc* 2009; 70:246.
 54. Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. *Gastrointest Endosc* 2010; 72:523.
 55. Capelle LG, Haringsma J, de Vries AC, et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. *Dig Dis Sci* 2010; 55:3442.
 56. Sobrino-Cossío S, Abdo Francis JM, Emura F, et al. Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia. *Rev Gastroenterol Mex (Engl Ed)* 2018; 83:245.
 57. Esposito G, Pimentel-Nunes P, Angeletti S, et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. *Endoscopy* 2019; 51:515.

58. Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. *Gastrointest Endosc* 2017; 86:857.
59. Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. *Endoscopy* 2012; 44:236.
60. Savarino E, Corbo M, Dulbecco P, et al. Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. *World J Gastroenterol* 2013; 19:2668.
61. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of *Helicobacter pylori* or intestinal metaplasia: role of the Sydney System. *Hum Pathol* 1999; 30:72.
62. Guarner J, Herrera-Goepfert R, Mohar A, et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. *Hum Pathol* 2003; 34:28.
63. Eriksson NK, Färkkilä MA, Voutilainen ME, Arkkila PE. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. *Endoscopy* 2005; 37:532.
64. de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. *Helicobacter* 2010; 15:259.
65. Rugge M, Farinati F, Di Mario F, et al. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. *Hum Pathol* 1991; 22:1002.
66. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of *Helicobacter pylori* infection and the assessment of the extent of atrophic gastritis. *Am J Gastroenterol* 1998; 93:569.
67. Rodríguez-Carrasco M, Libânio D, Dinis-Ribeiro M, Pimentel-Nunes P. Where should gastric biopsies be performed when areas of intestinal metaplasia are observed? *Endosc Int Open* 2019; 7:E1636.
68. Shinozaki S, Osawa H, Hayashi Y, et al. Linked color imaging for the detection of early gastrointestinal neoplasms. *Therap Adv Gastroenterol* 2019; 12:1756284819885246.
69. Castro R, Rodriguez M, Libânio D, et al. Reliability and accuracy of blue light imaging for staging of intestinal metaplasia in the stomach. *Scand J Gastroenterol* 2019; 54:1301.
70. Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. *Clin Gastroenterol Hepatol* 2014; 12:368.
71. Bok GH, Jeon SR, Cho JY, et al. The accuracy of probe-based confocal endomicroscopy versus conventional endoscopic biopsies for the diagnosis of superficial gastric neoplasia

- (with videos). *Gastrointest Endosc* 2013; 77:899.
72. Pittayanon R, Rerknimitr R. Role of digital chromoendoscopy and confocal laser endomicroscopy for gastric intestinal metaplasia and cancer surveillance. *World J Gastrointest Endosc* 2012; 4:472.
 73. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. *Gastrointest Endosc* 2003; 57:498.
 74. Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. *Gastrointest Endosc* 2008; 67:1011.
 75. Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen* 2004; 11:141.
 76. Huang YK, Yu JC, Kang WM, et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. *PLoS One* 2015; 10:e0142080.
 77. Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and *Helicobacter pylori* seropositivity in Eastern Asians: a systematic review and meta-analysis. *PLoS One* 2014; 9:e109783.
 78. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-*Helicobacter pylori* IgG Antibody and Serum Pepsinogen Levels--The ABC Method. *Digestion* 2016; 93:13.
 79. Ikeda F, Shikata K, Hata J, et al. Combination of *Helicobacter pylori* Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. *J Epidemiol* 2016; 26:629.
 80. Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-*Helicobacter pylori* antibodies serum assays for the diagnosis of atrophic gastritis. *Aliment Pharmacol Ther* 2017; 46:657.
 81. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European *Helicobacter* and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. *Endoscopy* 2019; 51:365.
 82. Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. *Gut* 2019;

68:1545.


83. Shah SC, Gawron AJ, Mustafa RA, Piazuolo MB. Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice. *Gastroenterology* 2020; 158:745.
84. Hung KW, Maratt JK, Cho WK, et al. AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With *Helicobacter pylori*. *Gastroenterology* 2022; 163:3.
85. Pimanov SI, Makarenko EV, Voropaeva AV, et al. *Helicobacter pylori* eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. *J Gastroenterol Hepatol* 2008; 23:1666.
86. Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of *Helicobacter pylori* eradication on gastric histology: a systematic review and meta-analysis. *Helicobacter* 2007; 12 Suppl 2:32.
87. Watari J, Das KK, Amenta PS, et al. Effect of eradication of *Helicobacter pylori* on the histology and cellular phenotype of gastric intestinal metaplasia. *Clin Gastroenterol Hepatol* 2008; 6:409.
88. Ford AC, Forman D, Hunt R, et al. *Helicobacter pylori* eradication for the prevention of gastric neoplasia. *Cochrane Database Syst Rev* 2015; :CD005583.
89. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after *Helicobacter pylori* eradication: a meta-analysis. *Digestion* 2011; 83:253.
90. Mera RM, Bravo LE, Camargo MC, et al. Dynamics of *Helicobacter pylori* infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. *Gut* 2018; 67:1239.
91. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008; 372:392.
92. Choi IJ, Kook MC, Kim YI, et al. *Helicobacter pylori* Therapy for the Prevention of Metachronous Gastric Cancer. *N Engl J Med* 2018; 378:1085.
93. Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. *Gut* 2002; 50:378.
94. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. *Gut* 1991; 32:1110.
95. O'Connor A, McNamara D, O'Moráin CA. Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. *Cochrane Database Syst Rev* 2013; :CD009322.

96. Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2016; 28:1041.
97. Teh JL, Tan JR, Lau LJ, et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. *Clin Gastroenterol Hepatol* 2015; 13:480.
98. Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. *Eur J Cancer Prev* 2010; 19:288.
99. Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* 2003; 95:1784.
100. Yang HB, Cheng HC, Sheu BS, et al. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2007; 25:455.
101. Hung KH, Yang HB, Cheng HC, et al. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after *Helicobacter pylori* eradication. *J Gastroenterol Hepatol* 2010; 25:48.
102. Zhang LJ, Wang SY, Huo XH, et al. Anti-*Helicobacter pylori* therapy followed by celecoxib on progression of gastric precancerous lesions. *World J Gastroenterol* 2009; 15:2731.
103. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for *Helicobacter pylori* infection. *Gut* 2005; 54:1536.
104. Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. *Clin Cancer Res* 2006; 12:4766.
105. Plummer M, Vivas J, Lopez G, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. *J Natl Cancer Inst* 2007; 99:137.
106. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. *J Natl Cancer Inst* 2006; 98:974.
107. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-*helicobacter pylori* therapy. *J Natl Cancer Inst* 2000; 92:1881.

Topic 16636 Version 16.0

GRAPHICS


Complete gastric intestinal metaplasia



In complete intestinal metaplasia, the glands and foveolar epithelium are replaced by small intestine type mucosa with goblet cells, eosinophilic enterocytes and a "brush border."

Graphic 81064 Version 2.0

Incomplete gastric intestinal metaplasia



Incomplete intestinal metaplasia with colonic epithelium, multiple, irregular goblet cells without a brush border.

Graphic 77310 Version 2.0

OLGA staging system for identifying patients with metaplastic (chronic) atrophic gastritis who are at high risk for evolution to gastric cancer

Stage 0	Scores of 0 (no atrophy) in corpus and antrum
Stage I	Score of 1 (mild atrophy) in corpus with score of 0 or 1 in antrum, or score of 0 in corpus and score of 1 in antrum
Stage II	Score of 2 (moderate atrophy) or 3 (severe atrophy) in corpus with score of 0 in antrum, or score of 2 in corpus with score of 1 in antrum, or score of 0 or 1 in corpus with score of 2 in antrum
Stage III	Score of 3 in corpus with score of 1 in antrum, or score of 2 in corpus and 2 in antrum, or score of 0 or 1 in corpus with score of 3 in antrum
Stage IV	Scores of 3 in corpus and antrum, or score of 3 in corpus and 2 in antrum or score of 2 in corpus and 3 in antrum

OLGA: Operative Link for Gastritis Assessment.

Original table modified for this publication. From: Rugge M, Correa P, DiMario F, et al. OLGA staging for gastritis: A tutorial. Dig Liver Dis 2008; 40:650. Table used with the permission of Elsevier Inc. All rights reserved.

Graphic 121370 Version 2.0

OLGIM staging system for identifying patients with metaplastic (chronic) atrophic gastritis who are at high risk for evolution to gastric cancer


Stage 0	Scores of 0 (no IM) in corpus and antrum
Stage I	Score of 1 (mild IM) in corpus with score of 0 or 1 in antrum, or score of 0 in corpus and score of 1 in antrum
Stage II	Score of 2 (moderate IM) or 3 (severe IM) in corpus with score of 0 in antrum; score of 2 in corpus with score of 1 in antrum; or score of 0 or 1 in corpus with score of 2 in antrum
Stage III	Score of 3 (severe IM) in corpus with score of 1 or 2 in antrum, or score of 0 or 1 in corpus with score of 3 in antrum
Stage IV	Scores of 3 in corpus and antrum, or score of 3 in corpus and 2 in antrum or score of 2 in corpus and 3 in antrum

IM: intestinal metaplasia.

Original table modified for this publication. From: Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointestinal Endoscopy 2010; 1150. Table used with the permission of Elsevier Inc. All rights reserved.

Graphic 116254 Version 1.0

Approach to the management of patients with gastric intestinal metaplasia



H. pylori: Helicobacter pylori.

* In patients with known risk factors for gastric cancer, who are amenable to endoscopic surveillance, we generally perform a repeat endoscopy with gastric biopsy mapping within one year. In patients without known risk factors for gastric cancer, but who are amenable to endoscopic surveillance if indicated, we perform a repeat upper endoscopy within three years.

¶ Infection with *H. pylori* is initially assessed by the histologic evaluation of gastric biopsy samples. In the event of negative biopsies for *H. pylori*, infection status should be determined with serology. Any patient with positive serology who does not have a definitive history of having been treated for *H. pylori* should receive treatment, even if biopsies are negative.

Δ General measures to decrease the risk of gastric cancer include smoking cessation and moderation of alcohol intake.


◇ Surveillance endoscopic evaluation includes detailed visual inspection with high-resolution endoscopes, narrow band imaging if there is local expertise, and gastric biopsy mapping.

§ These recommendations do not apply to individuals with hereditary gastric cancer syndromes. Refer to UpToDate topics on gastric cancer for additional details.

¥ In patients with limited or complete GIM who do not have additional risk factors for gastric cancer, evidence to support routine endoscopic surveillance is lacking. GIM surveillance should be driven by shared patient-physician decision making.

Graphic 127117 Version 1.0

Gastric biopsy sampling protocol



- **(Panel A)** Sydney protocol biopsy sites in the anatomic view.
- **(Panel B)** Sydney protocol biopsy sites in the opened stomach along the greater curvature.
- **Gastric biopsies should be obtained from the following sites:**
 1. Distal antrum, lesser curvature, within 3 to 5 cm of pylorus
 2. Distal antrum, greater curvature, within 3 to 5 cm of pylorus
 3. Lesser curvature of the incisura angularis
 4. Proximal corpus, lesser curvature
 5. Proximal corpus, greater curvature

Adapted from: Nieuwenburg SA, Waddingham WW, Graham D. Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study. BMJ Open 2019; 9:e032013. Copyright © 2019 The Authors. Available at: <https://bmjopen.bmj.com/content/9/9/e032013> (Accessed on February 18, 2020). Reproduced under the terms of the [Creative Commons Attribution License](#).

Graphic 127130 Version 2.0

Contributor Disclosures

Douglas Morgan, MD, MPH Grant/Research/Clinical Trial Support: American Molecular Labs [Donated analysis – Gastric intestinal metaplasia, early gastric cancer]; CDx Diagnostics [Donated analysis – Gastric intestinal metaplasia, early gastric cancer]; Freenome Inc [Site PI – Gastric intestinal metaplasia, early gastric cancer]; Panbela Therapeutics [Donation of study drug – Gastric intestinal metaplasia, early gastric cancer]; Thorne Research [Donation of study drug – Gastric intestinal metaplasia, early gastric cancer]. All of the relevant financial relationships listed have been mitigated. **Mark Feldman, MD, MACP, AGAF, FACG** No relevant financial relationship(s) with ineligible companies to disclose. **Shilpa Grover, MD, MPH, AGAF** No relevant financial relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy](#)

→